Amgen raises 2016 outlook after Q1 earnings boost
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise
Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover
AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …
The mutual benefit of becoming one of Britain’s best workplaces
April 28, 2016Medical Communications great place to work, medical communications, medical communications agency
Imagine a company with a 100%-satisfied workforce. What could a team of such fulfilled employees really deliver to clients?
Abbott to purchase St Jude Medical in $25 billion deal
April 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing $25, 25 billion, Abbott, Medical device, acquisition, purchase, st jude medical
Abbott (NYSE: ABT) has announced an agreement to purchase device manufacturer, St Jude Medical, in a deal worth $25 billion. …
World Immunisation Week marked by ABPI reception in House of Commons
April 28, 2016Medical Communications ABPI, immunisations
The ABPI vaccine group joined a host of figures at a parliamentary reception to mark World Immunisation Week. Parliamentarians, policy …
Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises
April 28, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises
Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …
PTC Therapeutics appoints Tuyen Ong as chief medical officer
April 28, 2016Business Services, Research and Development
PTC Therapeutics (Nasdaq: PTCT) has named Tuyen Ong chief medical officer. He succeeds Robert Spiegel who will remain with the company …
Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud
April 28, 2016Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice
Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
SHL at the 2016 Prefillied Syringes Seminar Tokyo
April 28, 2016Manufacturing and Production
SHL is glad to announce that it is going to participate in the Prefilled Syringe Seminar 2016 Tokyo, organized by …
GlaxoSmithKline Q1 earnings up 14% on new product sales
April 27, 2016Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Q1, earnings, results, revenue, sales
GlaxoSmithKline (LSE: GSK) reported a 14% rise in first-quarter earnings driven by demand for new drugs. The UK drug firm …
New head of R&D at Biogen
April 27, 2016Research and Development Biogen, Pfizer, R&D, erhlers, michael, michael erhlers, research and development
Biogen (NASDAQ: BIIB) has announced the appointment of Dr Michael Ehlers as executive vice president, research and development. His role …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
NICE gives green light to Novartis’s heart drug Entresto
April 27, 2016Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients
NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …
Remaining in the EU is vital for UK’s cancer research strength, say leading oncologists
April 27, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, EU, Europe, UK, brexit, britain, cancer research, cede, exit, implications, negative, oncology, pharma
Leading UK oncologists have written an article in the May issue of The Lancet, strongly urging Britain to remain in …
Baxter hikes 2016 earnings view driven by strong Q1 results
April 27, 2016Research and Development, Sales and Marketing Baxalta, FY, Q1, baxter, earnings, outlook, results, revenue
Baxter International (NYSE: BAX) reported better-than-expected first-quarter profits and raised its earnings outlook for 2016. The company now sees earnings …
Eli Lilly Q1 earnings miss estimates, ups FY view; shares drop 2%
April 27, 2016Research and Development, Sales and Marketing Eli Lilly, FY, Q1, earnings, revenue, sales
Shares in US drugmaker Eli Lilly (NYSE: LLY) dropped to close down over 2% Tuesday after the company posted first-quarter …
ABPI welcomes recommendations from NHS specialised services report
April 27, 2016Research and Development, Sales and Marketing ABPI, NHS, NHS England, NICE, National Audit Office, report, specialised services
The ABPI has welcomed the findings of a National Audit Office report on the commission of specialised service by NHS …
Shire to close Hampshire base and relocate jobs, say reports
April 27, 2016Manufacturing and Production, Research and Development Jobs, Shire, close, factory, hampshire, loss, relocate
Shire is set to cease operations at its site in Basingstoke, Hampshire, by the end of next year and relocate …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
